<DOC>
	<DOC>NCT02106845</DOC>
	<brief_summary>Evaluate the effect of regorafenib on the pharmacokinetics of digoxin (P-gp substrate : P-glycoprotein) and rosuvastatin (BCRP substrate: Breast cancer resistant protein) by comparing their Area under time curve (AUC(0-24)) and maximum drug concentration (Cmax) on Day -7 and Cycle 1 or Cycle 2 Day 15 of regorafenib in cancer patients</brief_summary>
	<brief_title>Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>The following criteria apply to ALL patients starting the study treatment: Patients with histologically confirmed, locally advanced or metastatic solid tumors refractory to standard therapy or in whom regorafenib is considered a standard treatment. Male or Female Caucasian patients &gt;/= 18 years of age Women of childbearing potential and men must agree to use adequate contraception before entering the program until at least 8 weeks after the last study drug administration. Life expectancy of at leat 12 weeks Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 Adequate bone marrow and liver function Estimated creatinine clearance (CLcr) â‰¥ 30 mL/min as calculated using the CockroftGault (CG) equation. Thyroid Stimulating Hormone(TSH) within normal ranges. The following inclusion criteria apply to Group A (digoxin + regorafenib) patients ONLY: Potassium, magnesium and calcium blood levels within normal range according to the local laboratory. The following inclusion criteria apply to Group B (rosuvastatin + regorafenib) patients ONLY: Signed genetic informed consent. Patients must be able to understand and willing to sign the written informed consent intended to screen for BCRP and OATP1B1 polymorphisms. For ALL patients Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before start of study medication. Nonhealing wound, skin ulcer, or bone fracture. Ongoing or active infection. Other anticancer treatment. Patients unable to swallow oral medications For Group A (digoxin + regorafenib): Family history of sudden cardiac death. For Group B (rosuvastatin + regorafenib): Patients with porphyria. Patients with intestinal or urinary obstructions.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>Probe substrates</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Cancer</keyword>
	<keyword>Safety</keyword>
	<keyword>Advanced solid malignant tumors</keyword>
</DOC>